The Brooklyn Park, Minnesota–based neuromodulation implant developer reported a loss of $10.57 million, or $0.52 per diluted share, on sales of $3.7 million for the three months ended Dec. 31, 2021, for a bottom-line loss of 210% and sales growth of 75% compared with Q4 2020.
The loss was 8¢ per share deeper than expected by the Street, where analysts were looking for EPS of –44¢ on sales of $3.86 million.